Interleukin-1 receptor-like 1 (IL1RL1), also known as ST2, is a member of the interleukin-1 receptor family. This receptor is encoded by the IL1RL1 gene and plays a crucial role in the immune system by mediating responses to interleukin-33 (IL-33), a cytokine involved in inflammatory and immune responses .
IL1RL1 is a transmembrane protein that consists of three extracellular immunoglobulin-like domains, a single transmembrane domain, and an intracellular Toll/IL-1 receptor (TIR) domain. The extracellular domains are responsible for binding IL-33, while the TIR domain is involved in signal transduction .
Upon binding to IL-33, IL1RL1 forms a complex with the IL-1 receptor accessory protein (IL-1RAcP), which initiates a signaling cascade that activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinases (MAPKs). These pathways lead to the production of pro-inflammatory cytokines and chemokines, which are essential for immune responses .
IL1RL1 is expressed in various cell types, including mast cells, eosinophils, basophils, and Th2 cells. It is particularly important in the context of allergic inflammation and asthma, where it contributes to the activation and recruitment of immune cells to sites of inflammation .
In addition to its role in allergic diseases, IL1RL1 has been implicated in other conditions such as cardiovascular diseases, autoimmune disorders, and cancer. For example, elevated levels of IL1RL1 have been observed in patients with heart failure, suggesting a potential role in the pathogenesis of this condition .
Recombinant human IL1RL1 is produced using recombinant DNA technology, which involves inserting the IL1RL1 gene into an expression vector and introducing it into a host cell, such as Escherichia coli or Chinese hamster ovary (CHO) cells. The host cells then produce the IL1RL1 protein, which can be purified and used for research or therapeutic purposes .
Recombinant IL1RL1 is valuable for studying the receptor’s structure and function, as well as for developing potential therapeutic interventions targeting IL1RL1-mediated pathways. For instance, recombinant IL1RL1 can be used to screen for small molecules or antibodies that inhibit IL-33 binding, which may have therapeutic potential in treating allergic and inflammatory diseases .